On 7 July 2026, Argent BioPharma announced a binding transaction framework for the exclusive global licensing of CannEpil — its cannabinoid therapy for drug-resistant epilepsy — to Splash Beverage Group (NYSE American: SBEV). The transaction provides US$5.5 million in upfront consideration, satisfied through the forgiveness of the company's entire outstanding Mercer Street convertible debt. Key terms of the deal: Argent retains 100% ownership of all CannEpil intellectual property; receives a 15% net revenue royalty on future SBEV global CannEpil sales; retains the right to manufacture CannEpil for SBEV (with capped pricing); and the Mercer debt — a principal secured liability — is completely eliminated from the balance sheet. SBEV must file an FDA New Drug Application following successful clinical trials and must initiate a Phase I clinical trial within 24 months.

Argent BioPharma Ltd (ASX:RGT) surged 168.57% in the latest session on significant news, with shares trading at $0.094 on 7 Jul 2026. The move draws investor attention to the latest developments at the company and what they may mean for the near and longer-term investment case. For investors evaluating Argent BioPharma Ltd, understanding the company's business, the significance of recent announcements and the key risks and opportunities provides an essential foundation for informed decision-making.

Company Overview

Argent BioPharma Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. The company's lead asset CannEpil is a pharmaceutical-grade cannabinoid combination therapy (CBD:THC at 20:1 ratio) developed for drug-resistant epilepsy. CannEpil has established regulatory and commercial access pathways in Ireland, the UK, Germany and Australia, with full reimbursement status in Ireland under the Medicinal Cannabis Access Programme. The company has now licensed global commercialisation rights to Splash Beverage Group while retaining IP ownership, manufacturing rights and royalties.

Business at a Glance

Argent BioPharma trades on the Australian Securities Exchange under the ticker ASX:RGT. Following the CannEpil licence transaction, the company will focus on its broader neuro-immune portfolio and US growth strategy while retaining participation in CannEpil's commercial success.

• CannEpil — pharmaceutical-grade CBD:THC therapy for drug-resistant epilepsy

• Global licensing to SBEV — exclusive worldwide licence for commercialisation

• 15% net revenue royalty — perpetual participation in CannEpil revenues

• Manufacturing rights retained — Argent as primary CannEpil manufacturer

• CimetrA — second asset targeting inflammatory conditions

• Neuro-immune portfolio — broader pipeline beyond CannEpil

Strategic Positioning

The CannEpil licensing transaction is a strategic milestone that simultaneously delivers upfront value (US$5.5 million), eliminates the primary balance sheet overhang (Mercer convertible debt), preserves long-term economic participation (royalties and manufacturing) and frees management focus for the broader pipeline. The transaction positions Argent to advance toward a US national exchange listing while participating in CannEpil's global commercialisation through royalties and manufacturing revenues without bearing the full cost of global commercial execution.

Recent Market Context

Drug-resistant epilepsy affects approximately one-third of all epilepsy patients globally and represents one of the largest unmet needs in neurology. CannEpil has established a commercial and regulatory footprint in Europe and Australia, with the FDA IND providing a US pathway. The 168.57% share price surge on announcement day reflects the market's assessment of the transformative nature of debt elimination combined with preserved royalty participation — a structure that has materially changed the company's financial and strategic outlook.

Why Investors May Be Watching Argent BioPharma Ltd

The CannEpil deal is the dominant near-term investment narrative for RGT. The full elimination of the Mercer secured debt removes a significant financial overhang, while the 15% royalty and manufacturing rights preserve long-term upside from CannEpil without requiring Argent to fund global commercial execution. Progress toward a US national exchange listing, SBEV's execution of its clinical obligations and the development of Argent's broader neuro-immune portfolio are the key post-transaction milestones investors will monitor.

The Pharmaceutical Licensing & Cannabinoid Therapeutics Industry

The pharmaceutical cannabinoid therapeutics sector is a specialised and regulated segment distinct from the broader cannabis industry. Companies developing pharmaceutical-grade cannabinoid therapies with clinical evidence, regulatory pathways and reimbursement access occupy a more defensible market position than consumer cannabis brands. Drug-resistant epilepsy remains a major unmet need, with existing treatments failing approximately one-third of patients and creating a clear clinical case for alternative therapeutic approaches.

Where Argent BioPharma Ltd Fits Within the Sector

Argent BioPharma is a small clinical-stage pharmaceutical company that has built a commercially validated cannabinoid epilepsy therapy and is now transitioning to a royalty and manufacturing model for CannEpil while retaining its broader pipeline. The CannEpil licensing structure is a creative solution to balance sheet challenges while preserving long-term value.

Key Catalysts Investors May Monitor

Investors following Argent BioPharma Ltd may monitor several developments:

• Mercer debt elimination — completion of the transaction conditions

• SBEV Phase I clinical trial initiation — required within 24 months

• CannEpil royalty payments commencing with SBEV commercial activity

• US national exchange listing progress

• CimetrA and broader neuro-immune portfolio development

• Manufacturing revenues from CannEpil supply to SBEV

• FDA IND progression for CannEpil in the US

• Shareholder and regulatory approvals for transaction completion

Key Risks and Uncertainties

The transaction remains subject to conditions precedent including shareholder and board approvals and completion of the Mercer debt exchange. SBEV's ability to execute on its clinical and commercial obligations under the licence is a key risk for the royalty and manufacturing revenue streams. Argent's CannEpil royalty income is dependent on SBEV achieving regulatory approval and commercial success — outcomes that are uncertain and long-dated. The company still requires capital to fund its broader pipeline.

Balanced Outlook

The immediate outlook is dominated by transaction completion — satisfying the conditions precedent including shareholder approval. Once complete, Argent will have a materially stronger balance sheet and can focus on its broader pipeline and US listing strategy. Longer-term, the royalty and manufacturing stream from CannEpil provides a valuable ongoing participation in the product's success, with the timing and magnitude of royalty income dependent on SBEV's clinical and commercial execution.

Considerations That May Support Interest

• US$5.5 million consideration eliminates entire Mercer secured debt — transformative for balance sheet

• 15% perpetual royalty on global CannEpil revenues preserves long-term economic participation

• 100% CannEpil IP ownership retained — protecting future development optionality

• Manufacturing rights retained — ongoing commercial revenue participation

• Strategic clarity to advance broader neuro-immune portfolio and US listing

Considerations That Warrant Caution

• Transaction subject to conditions precedent including shareholder and board approvals

• SBEV royalty income dependent on successful clinical trials and regulatory approval

• Long and uncertain timeline to US FDA approval and commercial royalty payments

• Company still requires capital to fund broader pipeline beyond CannEpil

• SBEV's capacity to execute clinical and commercial obligations is a key risk

Conclusion

Argent BioPharma's CannEpil licensing transaction is a creative and strategically sound deal that addresses the company's most pressing financial challenge — its Mercer convertible debt — while preserving meaningful long-term participation in CannEpil's commercial success through royalties, manufacturing rights and retained IP ownership. The structure reflects thoughtful deal-making that balances near-term financial relief with long-term value preservation. For investors assessing what the deal means for RGT's future, the key questions are whether the transaction conditions are satisfied in the expected timeframe, whether SBEV has the capability and commitment to advance CannEpil through US clinical development, and what the company's broader pipeline can deliver as the management focus sharpens post-transaction.